Fig. 2
iP subunit deficiency has no impact on cerebral Aβ burden in young and aged APPPS1 mice. a Representative images of diffuse plaques (4G8 antibody immunohistochemistry) and congophilic core plaques assessed by Congo Red staining in cortical sections of young and aged APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice (scale bar 100 μm) and (b) corresponding stereomorphological quantification of Aβ plaque burden (n = 4–8 mice per group, p > 0.05, Mann-Whitney test). c Plaque size distribution analysis using the CellSense software in the cerebral cortex of 120 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice and (d) aged 250 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice (n = 3–5 mice per group, p > 0.05, two-way ANOVA, followed by Bonferroni post-tests). e Total amounts of soluble and insoluble Aβ1–40 and Aβ1–42 species in brain homogenates of pre-plaque depositing, young 120 days old and aged250 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice assessed by MSD 96-Well MULTI-SPOT® Human (6E10) Abeta Triplex Assay (Meso Scale Discovery) (n = 4–8 mice per group, p > 0.05, one-way ANOVA followed by Bonferroni post-tests). f and (g) Amount of soluble and insoluble Aβ1–40 and Aβ1–42 species calculated from individual protein fractions assessed by MSD 96-Well MULTI-SPOT® Human (6E10) Abeta Triplex Assay (Meso Scale Discovery) in brain homogenates of (f) young 120 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice (n = 4–6 mice per group, p > 0.05, Mann-Whitney test) and (g) aged 250 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice (n = 5 mice per group, p > 0.05, Mann-Whitney test)